JDB153 / Jumbo Drug Bank - LARVOL DELTA

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: West China Hospital | Trial completion date: Oct 2027 ➔ Dec 2028 | Initiation date: Oct 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2027 ➔ Sep 2028

Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Pancreatic Cancer • Solid Tumor

Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory to standard treatment: a single-arm, phase Ib/II study protocol. (PubMed, Front Pharmacol) - P1/2 | "Immunotherapy alone often fails in this disease due to the immunosuppressive microenvironment. By combining MNK/VEGFR inhibition with PD-1 blockade, this study investigates a promising strategy to overcome immune resistance and establish a novel treatment paradigm for advanced pancreatic adenocarcinoma."

IO biomarker • Journal • P1/2 data • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: West China Hospital

New P1/2 trial • Oncology • Pancreatic Cancer • Solid Tumor

JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure (clinicaltrials.gov) - P1/2 | N=10 | Not yet recruiting | Sponsor: West China Hospital

New P1/2 trial • Hepatocellular Cancer • Oncology • Solid Tumor